SIGLEC6 and colorectal carcinoma: Morphometric analyses performed on CRC samples from the validation cohort substantiated the survival data of patients from the PanCancer collection, revealing that the mean percentage of BTLA and SIGLEC6 positive cells was significantly (p<0.0001) higher in short-term survivors than in long-term survivors.